DexCom's Continuous Glucose Monitoring Franchise — Sensor Leadership Meets Margin Recovery

DexCom, Inc. develops and sells continuous glucose monitoring (CGM) systems for people with diabetes and, more recently, for broader metabolic health use. The company's core products are the G6 and G7 sensor platforms, which transmit interstitial glucose readings to a receiver, smartphone, or insulin pump every five minutes, eliminating the need for fingerstick calibration in most use cases.

How the company makes money: Revenue is dominated by disposable sensors, which patients replace continuously, supplemented by transmitters, receivers, and mobile app subscriptions. The overwhelming majority of revenue is recurring in nature. DexCom sells primarily through distributors and direct channels into the pharmacy and durable medical equipment benefit pathways in the U.S., and through distributors internationally.

Customers: The primary customer base is people with type 1 and type 2 diabetes using intensive insulin therapy, reimbursed largely by commercial insurers, Medicare, and national health systems outside the U.S. The Stelo launch extends the customer base to adults with type 2 diabetes not using insulin, sold over the counter in the U.S.

Scale: With a $30.9B market cap, 377.36M shares outstanding, and a public float of 376.00M shares, DexCom is a large-cap medtech name with essentially fully distributed ownership. The company generates annual revenue in the multi-billion-dollar range and employs thousands globally, with manufacturing concentrated in the U.S. and Malaysia.

Near-term (next 4–8 quarters):

• U.S. sensor volume growth driven by G7 share gains among insulin pump users and improved prior-authorization workflows in the pharmacy channel.
• Stelo ramp as the over-the-counter channel builds, with initial revenue likely modest but the strategic value in establishing a consumer brand substantial.
• International expansion in Europe and Asia-Pacific, where CGM reimbursement is broadening and penetration remains well below U.S. levels.
• Margin recovery as G7 manufacturing yields improve and rebate intensity normalizes.

Medium-term (3–5 years):

• Basal-only type 2 penetration, a population several times the intensive-insulin base, contingent on reimbursement expansion and clinical guideline inclusion.
• Hospital and institutional use, where CGM adoption is early and carries higher per-unit pricing.
• Data and software monetization, including partnerships with insulin delivery companies and digital health platforms.
• Adjacent metabolic indications, where CGM data may support prediabetes and wellness applications.

Projections are illustrative estimates derived from the company's historical trajectory and disclosed guidance framework; historical figures are approximate.

The revenue deceleration from 24.4% in FY2023 to roughly 11% in FY2024 reflects a combination of U.S. rebate pressure, a softer insulin pump upgrade cycle, and the lapping of a strong prior-year comparison. The recovery embedded in our projections rests on Stelo contribution, international expansion, and stabilization of U.S. pricing. Gross margin compression to 60.5% in FY2024 was driven by G7 manufacturing ramp costs and higher rebate expense; the projected recovery to 63.5% by FY2026 assumes yield improvement and a more favorable channel mix. EPS growth outpacing revenue growth is the central financial thesis.

The global CGM market is estimated in the high single-digit billions of dollars annually and is projected to grow at a low-to-mid teens compound rate over the next five years, driven by diabetes prevalence, reimbursement expansion, and the shift from fingerstick testing to continuous monitoring. Including the broader type 2 and prediabetes populations, the total addressable market expands into the tens of billions.

Competitive positioning: DexCom holds a leading share of the U.S. CGM market alongside Abbott, with the two companies accounting for the vast majority of global volume. DexCom's differentiation rests on accuracy, integration breadth with insulin delivery systems, and clinical evidence depth; Abbott's FreeStyle Libre franchise competes aggressively on price and has a strong international footprint.

Comparable companies:

• Abbott Laboratories (ABT) — FreeStyle Libre, the primary global competitor in CGM, with a scale advantage in international markets and consumer pricing.
• Medtronic (MDT) — Guardian CGM integrated with its insulin pump franchise; a smaller but strategically important competitor in the automated insulin delivery ecosystem.
• Tandem Diabetes Care (TNDM) — Insulin pump maker and key DexCom integration partner; a bellwether for the automated insulin delivery market that drives CGM attach rates.
• Insulet (PODD) — Omnipod maker and another major DexCom partner, with strong growth in type 2 insulin users.

DCF discussion: A discounted cash flow approach anchored on mid-teens revenue growth tapering to mid-single digits by year ten, operating margins expanding toward the high teens to low 20s, and a weighted average cost of capital in the 7.5–8.5% range (reflecting the 1.48 beta and a modest debt weight) supports a fair value range broadly consistent with the current price. The key sensitivities are the terminal operating margin assumption and the pace of gross margin recovery; a 200bp difference in steady-state operating margin moves intrinsic value by roughly 15–20%.

Comparable multiples:

DexCom's multiple sits between the diversified medtech comps and the high-growth diabetes specialists, which we view as appropriate given its growth and margin profile. Relative to Insulet, DexCom trades at a discount on both P/E and EV/Revenue despite comparable end-market exposure, a gap that should narrow if margin recovery materializes.

• Reimbursement and pricing pressure: U.S. commercial payers and Medicare continue to push for lower CGM pricing, and any adverse coverage decision or step-therapy expansion could compress revenue per user and margins simultaneously.
• Competitive intensity from Abbott: FreeStyle Libre's price-led strategy, particularly in international markets and the over-the-counter segment, could limit DexCom's pricing power and slow Stelo adoption.
• Manufacturing execution: G7 yield and cost improvements are central to the margin thesis; production disruptions or slower-than-expected automation could delay gross margin recovery.
• Regulatory and clinical risk: CGM accuracy claims, software cybersecurity requirements, and FDA review timelines for new indications carry the potential for delay or restriction.
• Macro and currency exposure: With a 1.48 beta and meaningful international revenue, DXCM is sensitive to risk-off episodes and dollar strength, both of which can pressure reported results independent of underlying demand.